Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) had its target price decreased by BMO Capital Markets from $491.00 to $479.00 in a report released on Thursday. BMO Capital Markets currently has a market perform rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the company. Citigroup Inc. restated a buy rating and set a $480.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday. Goldman Sachs Group, Inc. (The) restated a neutral rating and set a $472.00 price objective (up previously from $469.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Jefferies Group LLC restated a hold rating and set a $471.00 price objective (up previously from $418.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Leerink Swann reaffirmed an outperform rating and set a $580.00 target price (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Finally, Morgan Stanley reaffirmed an equal weight rating and set a $450.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 23rd. Three analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. Regeneron Pharmaceuticals currently has a consensus rating of Hold and an average price target of $481.49.

Shares of Regeneron Pharmaceuticals (REGN) traded down $1.67 during midday trading on Thursday, reaching $404.54. The company’s stock had a trading volume of 771,100 shares, compared to its average volume of 888,846. Regeneron Pharmaceuticals has a 12-month low of $340.09 and a 12-month high of $543.55. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. The firm has a market cap of $43,346.87, a price-to-earnings ratio of 35.03, a PEG ratio of 1.56 and a beta of 1.56.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, beating analysts’ consensus estimates of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The firm had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. During the same quarter last year, the firm earned $3.13 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 23.0% on a year-over-year basis. equities analysts anticipate that Regeneron Pharmaceuticals will post 13.77 EPS for the current year.

WARNING: This piece was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/11/13/regeneron-pharmaceuticals-inc-regn-pt-lowered-to-479-00-at-bmo-capital-markets.html.

In other news, Chairman P Roy Vagelos sold 10,986 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $470.17, for a total transaction of $5,165,287.62. Following the transaction, the chairman now directly owns 329,543 shares in the company, valued at approximately $154,941,232.31. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Charles A. Baker sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, September 29th. The shares were sold at an average price of $450.00, for a total value of $900,000.00. Following the transaction, the director now owns 11,000 shares in the company, valued at $4,950,000. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 88,942 shares of company stock worth $42,064,076. 10.80% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of REGN. AQR Capital Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 201.4% in the 1st quarter. AQR Capital Management LLC now owns 8,805 shares of the biopharmaceutical company’s stock worth $3,412,000 after acquiring an additional 5,884 shares during the last quarter. Tudor Investment Corp ET AL acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth $233,000. Atria Investments LLC grew its holdings in shares of Regeneron Pharmaceuticals by 7.9% in the 2nd quarter. Atria Investments LLC now owns 1,168 shares of the biopharmaceutical company’s stock worth $574,000 after acquiring an additional 86 shares during the last quarter. Fisher Asset Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 75.1% in the 2nd quarter. Fisher Asset Management LLC now owns 1,411 shares of the biopharmaceutical company’s stock worth $693,000 after acquiring an additional 605 shares during the last quarter. Finally, National Pension Service grew its holdings in shares of Regeneron Pharmaceuticals by 10.8% in the 2nd quarter. National Pension Service now owns 66,518 shares of the biopharmaceutical company’s stock worth $33,920,000 after acquiring an additional 6,481 shares during the last quarter. Institutional investors and hedge funds own 67.80% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.